Azzalure 125iu

Specialized Aesthetic Neurotoxin for Precision Treatment

Azzalure® 125IU represents a specialized formulation of abobotulinumtoxinA, specifically developed and calibrated for aesthetic medical applications. As a botulinum toxin type A product, Azzalure® is designed with the aesthetic practitioner in mind, offering a unit strength that facilitates precise dosing for one of the most common treatment areas: the glabellar complex (the vertical frown lines between the eyebrows). Its formulation provides a reliable balance between localized effect and appropriate diffusion, allowing practitioners to achieve natural-looking softening of expression lines while preserving the patient’s ability to maintain authentic facial expressions.

Targeted Action for Predictable Aesthetic Outcomes

The clinical profile of Azzalure® 125IU is characterized by its targeted approach to glabellar line correction. The product’s pharmacological action temporarily reduces the contraction of the procerus and corrugator muscles responsible for creating frown lines. Patients typically begin to see initial improvement within 2-3 days, with full effects noticeable within one to two weeks. This relatively rapid onset contributes to high patient satisfaction, as individuals quickly observe a smoother, more relaxed appearance in their central facial expression zone. The 125IU presentation is specifically calibrated to provide sufficient units for effective treatment of the glabellar region in most patients, making it a practical and efficient choice for aesthetic practices.

Key Professional Features & Clinical Benefits:

• Optimal for Glabellar Complex: Specifically indicated and dosed for effective treatment of moderate to severe glabellar lines, allowing for standardized yet customizable treatment protocols.

• Predictable Diffusion Profile: Engineered to provide appropriate spread for the target muscles while minimizing unwanted effects on adjacent areas, offering practitioners greater control.

• Rapid Visible Results: Patients often notice initial effects within days, with full correction typically achieved within 1-2 weeks post-treatment.

• Calibrated Presentation: The 125IU vial size is designed to match the typical dosage requirements for the glabellar area, potentially reducing product waste and simplifying inventory management.

• Quality Assurance: Manufactured under stringent pharmaceutical standards to ensure consistent purity, potency, and reliability in every vial.

• Natural Expression Preservation: When correctly administered, effectively reduces frown lines while allowing for normal, expressive eyebrow movement.

Technical Specifications & Professional Protocol:

• Active Substance: AbobotulinumtoxinA (Botulinum Toxin Type A)

• Presentation: 125 International Units (IU) per single-use sterile glass vial

• Pharmaceutical Form: Lyophilized powder for solution for injection

• Primary Indication: Temporary improvement in the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows) in adults.

• Important Dosing Note: Azzalure® uses its own specific unit measurement. Units are not biologically equivalent to those of other botulinum toxin products. Dosing must be based on Azzalure®-specific guidelines, clinical experience, and individual patient assessment.

• Reconstitution: Must be reconstituted exclusively with sterile 0.9% sodium chloride (preservative-free saline) according to the manufacturer’s instructions and the practitioner’s established protocol.

• Storage Conditions: Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. The reconstituted product should be used immediately.

• Professional Administration: Azzalure® is a prescription-only medicinal product. It must be administered by a qualified healthcare professional with appropriate training in facial anatomy, injection techniques, and the management of potential complications. A full medical consultation is required prior to treatment.